2020
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Theurer S, Hager T, Herold T, Kalbourtzis S, Bankfalvi A, Schmid KW, Führer D, Aigner C, Hegedűs B. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. Pathology & Oncology Research 2020, 26: 2523-2535. PMID: 32591993, PMCID: PMC7471186, DOI: 10.1007/s12253-020-00834-y.Peer-Reviewed Original ResearchConceptsPD-L1 expressionAnaplastic thyroid cancerPapillary thyroid cancerHDAC inhibitor treatmentThyroid cancerInhibitor treatmentHDAC inhibitionAdditional preclinical modelsAnaplastic thyroid cancer cell linesAnaplastic thyroid cancer cellsMalignant pleural effusionThyroid cancer cell linesNew therapeutic optionsThyroid cancer cellsCell linesCancer cell linesStandard chemotherapyFavorable prognosisMale patientsClinical outcomesNovel cell linePleural effusionTherapeutic optionsAggressive malignancyCell cycle arrest
2019
In a Novel Malignant Pleural Effusion Derived Anaplastic Thyroid Cancer Line PD-L1 Expression is Strongly Increased by HDAC Inhibitor Treatment
Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Schmid K, Führer D, Aigner C, Hegedűs B. In a Novel Malignant Pleural Effusion Derived Anaplastic Thyroid Cancer Line PD-L1 Expression is Strongly Increased by HDAC Inhibitor Treatment. Pneumologie 2019, 73: 111-111. DOI: 10.1055/s-0039-1678390.Peer-Reviewed Original ResearchPD-L1 expressionMalignant pleural effusionHDAC inhibitor treatmentPleural effusionInhibitor treatmentEffusion